Lumexa Imaging Swings to Q2 Profit, Reiterates 2026 Outlook
LMRI sits 86% above its 52-week low of $6.45.
Summary
Lumexa Imaging reported Q2 net income of $2.74 million, turning positive year-over-year, with revenue up 5.1% to $264.2 million and adjusted EPS of $0.20. The company reiterated full-year 2026 revenue guidance of $1.045-$1.097 billion and maintained adjusted EPS guidance of $0.71-$0.77, while narrowing adjusted EBITDA outlook to $235-$241 million. This follows the Q1 2026 swing to profitability and the June refinancing of $823 million in term loans, which reduced interest expenses. Advanced outpatient volume grew 6.8% consolidated, and the company opened four new imaging centers year-to-date, including a joint venture with Hospital for Special Surgery. The results confirm the company's turnaround trajectory and provide a solid base for the reiterated guidance.
At the time of this announcement, LMRI was trading at $12.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.45 to $19.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.